Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study

    June 2026 in “ Acta Dermato Venereologica ”
    XinChen Ke, Y Gao, J Huang … Wei Shi
    Studysummary This study evaluated the use of JAK inhibitors in patients with alopecia areata episodes lasting at least eight years and found that while the overall therapeutic response was limited, a subset of patients achieved meaningful hair regrowth, suggesting these treatments as a viable option.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on medicaljournalssweden.se →
    Discuss this study in the Community →

    Research cited in this study 10

    1. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase 1/2 Inhibitor, in Adults with Alopecia Areata: Results from the THRIVE-AA2 Phase 3, Randomized, Double-Blind, Controlled Trial Journal of the American Academy of Dermatology · 2025
    2. Effectiveness And Safety Of Baricitinib In Alopecia Areata: A Prospective Cohort Study Journal of Dermatological Treatment · 2025
    3. Alopecia Areata Nature Reviews Disease Primers · 2025
    4. Ivarmacitinib for the Treatment of Adults with Severe Alopecia Areata: Results from a Phase 3 Trial Journal of the American Academy of Dermatology · 2025
    5. Real-World Assessment of Disease Characteristics and Clinical Outcomes in Alopecia Areata in a Global Noninterventional Observational Cohort (ADAAGIO) Clinical and Experimental Dermatology · 2025
    6. Complete Blood Collection-Based Systemic Inflammation Biomarkers as a Severity Biomarker in Alopecia Areata: A Cross-Sectional Study Acta Dermato Venereologica · 2024
    7. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    8. Resident Memory T Cells in Autoimmune Skin Diseases Frontiers in immunology · 2021
    9. The Effect of JAK Inhibitor on Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells International Journal of Molecular Sciences · 2020
    10. Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth Science Advances · 2015